查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1888743

美国尿失禁药物市场规模、份额和趋势分析报告：按类型、药物类别、性别、分销管道、地区和细分市场预测（2025-2033 年）

U.S. Urinary Incontinence Therapeutics Market Size, Share & Trends Analysis Report By Type (Stress Incontinence, Urge Incontinence), By Drug Class, By Gender, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

美国尿失禁药物市场摘要

据估计，2024 年美国尿失禁药物市值为 15.5 亿美元，预计到 2033 年将达到 24.1 亿美元。

预计从2025年到2033年，该市场将以5.06%的复合年增长率成长。随着主要患者群体对先进治疗方法的需求不断增长，美国市场持续扩张。

持续成长的老年人口是推动尿失禁治疗需求成长的主要因素，而老年族群膀胱控制障碍的发生率很高。例如，根据StatPearls Publishing于2024年8月发布的报告，美国有1,300万人患有尿失禁，其中养老院居民的盛行率超过50%，长期居住（超过100天）居民的盛行率高达75%。 53%的居家老年人患有尿失禁。 11%的老年人需要住院治疗，出院时仍有23%的老年人有尿失禁。 20-39岁女性的尿失禁盛行率为7-37%，老年女性为9-39%，老年男性为11-34%（其中2-11%的人每天都会出现尿失禁）。在约8000万女性中，超过60%的人报告有相关症状。製药公司正在推出改良药物，以改善症状控制并提高患者的用药依从性。临床机构的教育工作也鼓励患者儘早寻求治疗。医疗机构正在采用最新的诊断通讯协定，以支持及时启动治疗。抗胆碱能药物、β3促效剂和联合治疗的日益普及推动了处方量的增长，而患者从症状控制不佳过渡到积极治疗的意愿增强，则推动了整体治疗接受度的提高。

市场扩张将进一步受到男性和女性对压力性尿失禁、急性尿失禁和混合性尿失禁认知度提高的推动。例如，Elsevier BV 于 2024 年 5 月发布的一份报告发现，美国成年人每天久坐超过 7 小时，出现急性尿失禁(UUI) 症状的可能性显着增加。与久坐时间较短的人相比，女性久坐超过 7 小时会增加压力性尿失禁 (SUI) 的风险，男性久坐超过 7 小时会增加混合性尿失禁 (MUI) 的风险。产后併发症的增加推动了对个人化药物的需求。临床医生表示，他们越来越倾向于采用微创治疗方法来支持长期症状缓解。製药公司正在推进开发平臺，以推出耐受性更好的药物。随着越来越多的患者寻求便捷的后续照护网路基地台，药局通路的客流量也不断增长。数位健康平台正在协助药物管理，并有助于提高患者对处方治疗方案的依从性。以病人为中心的护理路径的持续实施正在促进产品应用率的提高。

治疗领域的成长主要受膀胱控制相关疾病发生率上升的推动，例如肥胖、糖尿病和神经系统疾病。医院和专科诊所正在加强尿失禁护理项目，以简化病患评估流程。例如，根据美国泌尿系统协会2024年6月发布的报告，美国膀胱过动症（OAB）的盛行率估计为7%至27%，女性为9%至34%。约24%至45%的女性有不同程度的尿失禁，其中20至39岁女性的盛行率为7%至37%，60岁以上女性的盛行率约为9%至39%。老年男性中，OAB的盛行率为11%至34%，其中2%至11%的男性会出现每日症状。临床指引强调系统化的治疗方案，这增加了药物需求。泌尿系统和妇科医生强调早期疗育以减少长期併发症。产品创新着重于研发副作用更少、服用更舒适的药物。市场相关人员正投资教育宣导活动，鼓励患者及时就医。随着越来越多的人重视透过规范的治疗方案来改善生活质量，整体医疗服务利用率也不断提高。

目录

第一章调查方法和范围

第二章执行摘要

第三章美国尿失禁药物市场变数、趋势与范围

  • 市场谱系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章美国尿失禁药物市场：按类型分類的业务分析

  • 按类型分類的市场份额（2024 年和 2033 年）
  • 按类型分類的市场规模、预测和趋势分析（2021 年至 2033 年）
  • 应力性尿失禁
  • 急性尿失禁
  • 溢出性尿失禁
  • 功能性尿失禁
  • 其他的

第五章美国尿失禁药物市场：按药物类别分類的业务分析

  • 按药物类别分類的市场份额（2024 年和 2033 年）
  • 按药物类别分類的市场规模、预测和趋势分析（按药物类别划分，2021 年至 2033 年）
  • 抗胆碱能药物
  • β3-肾上腺素受体促效剂
  • α受体阻断剂
  • 雌激素
  • 去氨加压素
  • 三环抗忧郁药物
  • 其他的

第六章美国尿失禁药物市场：性别业务分析

  • 按性别分類的市场份额（2024 年和 2033 年）
  • 性别市场规模、预测与趋势分析（性别，2021-2033 年）
  • 男性
  • 女士

第七章美国尿失禁药物市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2024 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（按分销管道划分，2021-2033 年）
  • 医院药房
  • 零售药房
  • 网路药房

第八章 竞争情势

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Astellas Pharma
    • Urovant Sciences/Sumitomo Pharma America
    • AbbVie
    • Pfizer
    • Merck
    • Sanofi
    • Bayer
    • Eli Lilly
    • Teva Pharmaceutical Industries
    • Johnson &Johnson
Product Code: GVR-4-68040-811-3

U.S. Urinary Incontinence Therapeutics Market Summary

The U.S. urinary incontinence therapeutics market size was estimated at USD 1.55 billion in 2024 and is projected to reach USD 2.41 billion by 2033, growing at a CAGR of 5.06% from 2025 to 2033. The U.S. market is expanding as demand for advanced treatment options rises across key patient groups.

Growth is supported by a steady increase in the elderly population that presents higher rates of bladder control disorders. For instance, August 2024, StatPearls Publishing reported that in the U.S. urinary incontinence affected 13 million individuals; prevalence reached >=50 % in nursing-facility residents and >75 % in long-term (>100 days) residents; 53 % of homebound older adults were incontinent; hospital admission and discharge rates were 11 % and 23 %, respectively; women aged 20-39 showed 7-37 %; older women 9-39 %; older men 11-34 % with 2-11 % daily; and among ~80 million women, >60 % reported symptoms. Manufacturers introduce improved pharmacological agents that offer better symptom control and stronger adherence outcomes. Awareness programs conducted by clinical organizations help patients seek treatment at earlier stages. Healthcare providers adopt updated diagnostic protocols that support timely therapy initiation. Prescription volumes rise through broader use of anticholinergics, beta-3 agonists, and combination regimens. Patient willingness to transition from unmanaged symptoms to active treatment strengthens overall therapeutic uptake.

Market expansion is further influenced by growing recognition of stress, urge, and mixed incontinence across women and men. For instance, May 2024, Elsevier BV reported that in the United States adults who sat for >=7 hours per day had significantly higher odds of experiencing urinary urgency incontinence (UUI) symptoms; women had elevated odds of stress urinary incontinence (SUI) when sitting >=7 h; men had elevated odds of mixed urinary incontinence (MUI) when sitting >=7 h compared with those sitting less. Rising postpartum complications contribute to higher demand for tailored medications. Clinicians report increased preference for minimally invasive options that support long-term symptom relief. Pharmaceutical companies advance R&D pipelines that introduce drugs with improved tolerability profiles. Pharmacy channels record higher footfall as patients seek convenient access points for ongoing therapy. Digital health platforms support medication management and improve follow-through on prescribed regimens. Continuous introduction of patient-centric treatment pathways supports stronger product adoption.

Therapeutic growth is reinforced by rising cases linked to obesity, diabetes, and neurological conditions that impact bladder control. Hospitals and specialty clinics strengthen incontinence care programs that streamline patient evaluation. For instance, June 2024, American Urological Association reported that in the United States the prevalence of overactive bladder (OAB) was estimated at 7 %-27 % in men and 9 %-34 % in women; among women some degree of urinary incontinence was experienced by roughly 24 %-45 %; women aged 20-39 had 7 %-37 %; women older than 60 had approximately 9 %-39 % reporting daily symptoms; older men had rates of 11 %-34 % with daily occurrences in 2 %-11 %. Clinical guidelines highlight structured treatment sequences that elevate demand for pharmacological agents. Urologists and gynecologists emphasize early intervention to reduce long-term complications. Product innovation focuses on agents that deliver fewer side effects and improved dosing comfort. Market players invest in awareness initiatives that encourage patients to seek medical support without delay. Overall utilization increases as more individuals prioritize quality-of-life improvements through regulated therapy plans.

U.S. Urinary Incontinence Therapeutics Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. urinary incontinence therapeutics market report based on type, drug class, gender, and distribution channel:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Stress Incontinence
  • Urge Incontinence
  • Overflow Incontinence
  • Functional Incontinence
  • Others
  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • Anticholinergics
  • Beta-3 Adrenoceptor Agonists
  • Alpha Blockers
  • Estrogen
  • Desmopressin
  • Tricyclic Antidepressants
  • Others
  • Gender Outlook (Revenue, USD Million, 2021 - 2033)
  • Male
  • Female
  • Distribution ChannelsOutlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug Class
    • 1.2.3. Gender
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Urinary Incontinence Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Urinary Incontinence Therapeutics Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Stress Incontinence
    • 4.4.1. Stress Incontinence Market, 2021 - 2033 (USD Million)
  • 4.5. Urge Incontinence
    • 4.5.1. Urge Incontinence Market, 2021 - 2033 (USD Million)
  • 4.6. Overflow Incontinence
    • 4.6.1. Overflow Incontinence, 2021 - 2033 (USD Million)
  • 4.7. Functional Incontinence
    • 4.7.1. Functional Incontinence Market, 2021 - 2033 (USD Million)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Urinary Incontinence Therapeutics Market: Drug Class Business Analysis

  • 5.1. Drug Class Market Share, 2024 & 2033
  • 5.2. Drug Class Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 5.4. Anticholinergics
    • 5.4.1. Anticholinergics Market, 2021 - 2033 (USD Million)
  • 5.5. Beta-3 Adrenoceptor Agonists
    • 5.5.1. Beta-3 Adrenoceptor Agonists Market, 2021 - 2033 (USD Million)
  • 5.6. Alpha Blockers
    • 5.6.1. Alpha Blockers Market, 2021 - 2033 (USD Million)
  • 5.7. Estrogen
    • 5.7.1. Estrogen Market, 2021 - 2033 (USD Million)
  • 5.8. Desmopressin
    • 5.8.1. Desmopressin Market, 2021 - 2033 (USD Million)
  • 5.9. Tricyclic Antidepressants
    • 5.9.1. Tricyclic Antidepressants Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. U.S. Urinary Incontinence Therapeutics Market: Gender Business Analysis

  • 6.1. Gender Market Share, 2024 & 2033
  • 6.2. Gender Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Gender, 2021 to 2033 (USD Million)
  • 6.4. Male
    • 6.4.1. Male Market, 2021 - 2033 (USD Million)
  • 6.5. Female
    • 6.5.1. Female Market, 2021 - 2033 (USD Million)

Chapter 7. U.S. Urinary Incontinence Therapeutics Market: Distribution Channels Business Analysis

  • 7.1. Distribution Channels Market Share, 2024 & 2033
  • 7.2. Distribution Channels Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by distribution channels, 2021 to 2033 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Astellas Pharma
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Urovant Sciences / Sumitomo Pharma America
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. AbbVie
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Pfizer
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merck
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Sanofi
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bayer
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Eli Lilly
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Teva Pharmaceutical Industries
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Johnson & Johnson
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 US urinary incontinence therapeutics market, by type, 2021 - 2033 (USD Million)
  • Table 4 US urinary incontinence therapeutics market, by drug class, 2021 - 2033 (USD Million)
  • Table 5 US urinary incontinence therapeutics market, by gender, 2021 - 2033 (USD Million)
  • Table 6 US urinary incontinence therapeutics market, by distribution channels, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. urinary incontinence therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 U.S. urinary incontinence therapeutics market dynamics
  • Fig. 12 U.S. urinary incontinence therapeutics market: Porter's five forces analysis
  • Fig. 13 U.S. urinary incontinence therapeutics market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Stress Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 16 Urge Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 17 Overflow Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 18 Functional Incontinence market, 2021 - 2033 (USD Million)
  • Fig. 19 Others market, 2021 - 2033 (USD Million)
  • Fig. 20 Drug Class market, 2021 - 2033 (USD Million)
  • Fig. 21 Anticholinergics market, 2021 - 2033 (USD Million)
  • Fig. 22 Beta-3 Adrenoceptor Agonists market, 2021 - 2033 (USD Million)
  • Fig. 23 Alpha Blockers market, 2021 - 2033 (USD Million)
  • Fig. 24 Estrogen market, 2021 - 2033 (USD Million)
  • Fig. 25 Desmopressin market, 2021 - 2033 (USD Million)
  • Fig. 26 Tricyclic Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 27 Others market, 2021 - 2033 (USD Million)
  • Fig. 28 Gender market, 2021 - 2033 (USD Million)
  • Fig. 29 Male market, 2021 - 2033 (USD Million)
  • Fig. 30 Male market, 2021 - 2033 (USD Million)
  • Fig. 31 Female market, 2021 - 2033 (USD Million)
  • Fig. 32 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 33 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 34 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 35 Online Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 36 Company categorization
  • Fig. 37 Company market position analysis
  • Fig. 38 Strategic framework